NIAGARA Phase III trial shows IMFINZI® significantly reduces bladder cancer recurrence and death risk when combined with surgery.

The NIAGARA Phase III trial found that a perioperative regimen of IMFINZI® (durvalumab) significantly reduced the risk of cancer recurrence by 32% and death by 25% in patients with muscle-invasive bladder cancer, compared to neoadjuvant chemotherapy alone. This suggests that combining IMFINZI® with surgery may offer a more effective treatment option for this patient group.

September 15, 2024
14 Articles

Further Reading